PT  - JOURNAL ARTICLE
AU  - Pan, Jing
AU  - Li, Zhigang
AU  - Wang, Lin
AU  - Szymanski, Joshua
AU  - Romano, Maria
AU  - Yin, Dylan
AU  - Wang, Allen
AU  - Small, Thomas
AU  - Zou, Zhiying
AU  - Li, Jing
AU  - Witham, Greg
AU  - Wang, Li
AU  - Zhang, Yubei
AU  - Qi, Kai
AU  - Yin, Ray
TI  - COVID-19 Neutralizing Antibody Surveillance Testing for Fully Vaccinated Individuals During Delta Variant Spread
AID  - 10.1101/2021.10.01.21264371
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.10.01.21264371
4099  - http://medrxiv.org/content/early/2021/10/03/2021.10.01.21264371.short
4100  - http://medrxiv.org/content/early/2021/10/03/2021.10.01.21264371.full
AB  - We recently performed 568 rapid neutralizing antibody (NAb) tests on 164 fully vaccinated individuals who received either Moderna or Pfizer COVID-19 vaccine regimens over 7 weeks. The NAb levels against the wild type (WA1/2020), Delta, and Kappa variants were measured and compared. Depending on each individual’s medical condition and vaccination status, the NAb levels for most of the fully vaccinated people decreased within 2-6 months, while a small number of individuals either generated non-detectable amount of NAbs after full vaccination (e.g., immunocompromised), or had high NAb levels lasting beyond 6 months. Since the NAb levels vary significantly among different individuals and decrease over time, the deployment of a low-cost rapid test to monitor NAb levels against both the wild type and emerging variants among fully vaccinated individuals can play a very crucial role to control the current pandemic. Our study provides an example of using such a rapid NAb test to fill this currently unmet medical need.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe development of NIDS® COVID-19 Neutralizing Antibody Rapid Test is funded in part by US Army (special thanks to Ms. Janet Jensen for her guidance and support of this project).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:ANP Technologies Institutional Review Board (IORG0010734) reviewed and approved required consent form and process based on ethical guidelines from the US Department of Health and Human Services (HHS) that are available at https://www.hhs.gov/ohrp/education-and-outreach/revised-common-rule/revised-common-rule-q-and-a/index.html#informed-consent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesTesting data are available from the corresponding authors upon request.